Geneyx specializes in advanced DNA and RNA data analysis, offering solutions for Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), gene panels, and microarrays. Their platform accelerates the diagnostic process by transforming raw genetic data into clinical reports, thereby enhancing the efficiency of genomic and clinical cohort analysis. Geneyx employs AI-based algorithms to interpret genetic data, which is compatible with long-read sequencing technologies such as PacBio and Oxford Nanopore. Additionally, the platform integrates multi-omics data, combining DNA and RNA sequencing for comprehensive analysis. This capability is particularly beneficial for identifying novel genetic variants associated with various diseases, thereby promoting the goal of reducing undiagnosed conditions.

The Geneyx Analysis platform is designed to support a wide range of applications, including pharmacogenomics and carrier screening, providing insights into drug responses and metabolic processes. With a user-friendly interface and robust bioinformatics pipelines, the platform has demonstrated a high diagnostic yield and rapid turnaround times, making it a valuable tool for clinical and research settings. Geneyx's commitment to continuous improvement and customer support has garnered positive feedback from users, highlighting its effectiveness in analyzing complex genetic data and facilitating impactful discoveries in medical genetics.

United States

Geneyx offers best-in-class practices harnessing #geneticdata available to guide digital insights for rare and #germline disorders and diseases. We aim to enrich disease-specific, clinically relevant insights around risk prediction, diagnosis, prognosis, and treatment for clinical and #pharmaceutical organizations.


Geneyx

Company Details